# Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma

> **NCT02168101** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 9 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** MLN9708

## Key facts

- **NCT ID:** NCT02168101
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2019-02-01
- **Final completion:** 2019-02-01
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2020-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02168101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02168101, "Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02168101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*